紫外线治疗皮肤病临床应用专家共识

2019-12-30 中国康复医学会 中华皮肤科杂志.2019,52(12):872-877.

紫外线在银屑病、白癜风、皮肤淋巴瘤、特应性皮炎等皮肤病治疗中具有重要地位。近年来随着光医学技术的发展,更加安全高效的紫外线治疗技术在皮肤病治疗中得到推广应用。为提高紫外线治疗的疗效与安全性,本共识对紫外线治疗在皮肤科的临床规范应用提出具体建议,供临床医生在实践中参考。

中文标题:

紫外线治疗皮肤病临床应用专家共识

发布机构:

中国康复医学会

发布日期:

2019-12-30

简要介绍:

紫外线在银屑病、白癜风、皮肤淋巴瘤、特应性皮炎等皮肤病治疗中具有重要地位。近年来随着光医学技术的发展,更加安全高效的紫外线治疗技术在皮肤病治疗中得到推广应用。为提高紫外线治疗的疗效与安全性,本共识对紫外线治疗在皮肤科的临床规范应用提出具体建议,供临床医生在实践中参考。

 

拓展威廉亚洲博彩公司 :紫外线相关威廉亚洲博彩公司 :

相关资料下载:
[AttachmentFileName(sort=100, fileName=紫外线治疗皮肤病临床应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=914d41c001856667, title=紫外线治疗皮肤病临床应用专家共识, enTitle=, guiderFrom=中华皮肤科杂志.2019,52(12):872-877., authorId=null, author=, summary=紫外线在银屑病、白癜风、皮肤淋巴瘤、特应性皮炎等皮肤病治疗中具有重要地位。近年来随着光医学技术的发展,更加安全高效的紫外线治疗技术在皮肤病治疗中得到推广应用。为提高紫外线治疗的疗效与安全性,本共识对紫外线治疗在皮肤科的临床规范应用提出具体建议,供临床医生在实践中参考。 , cover=, journalId=null, articlesId=null, associationId=189, associationName=中国康复医学会, associationIntro=中国康复医学会是于1983年经卫生部批准成立并在民政部依法登记的全国性学术组织,1987年中国康复医学会加入中国科协,2001年加入国际物理医学与康复医学学会。, copyright=0, guiderPublishedTime=Mon Dec 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>紫外线在银屑病、白癜风、皮肤淋巴瘤、特应性皮炎等皮肤病治疗中具有重要地位。近年来随着光医学技术的发展,更加安全高效的紫外线治疗技术在皮肤病治疗中得到推广应用。为提高紫外线治疗的疗效与安全性,本共识对紫外线治疗在皮肤科的临床规范应用提出具体建议,供临床医生在实践中参考。 </P> <P> </P>拓展威廉亚洲博彩公司 :<strong>与<font color=red>紫外线</font>相关威廉亚洲博彩公司 :</strong><br><ul><li><a href="//www.nyrain.com/guideline/show_article.do?id=294361c001e3719d" title="窄谱中波紫外线家庭光疗临床应用专家共识" target=_blank>窄谱中波紫外线家庭光疗临床应用专家共识</a></li> 更多信息请点击:<a href="//www.nyrain.com/guideline/list.do?q=%E7%B4%AB%E5%A4%96%E7%BA%BF" target=_blank>有关紫外线更多威廉亚洲博彩公司 </a></ul>, tagList=[TagDto(tagId=99073, tagName=紫外线治疗), TagDto(tagId=113, tagName=皮肤病)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤性, tenant=100), CategoryDto(categoryId=95, categoryName=康复医学, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10850, appHits=290, showAppHits=15, pcHits=1858, showPcHits=9941, likes=29, shares=15, comments=10, approvalStatus=1, publishedTime=Mon Jan 27 20:25:31 CST 2020, publishedTimeString=2019-12-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 27 20:25:31 CST 2020, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:19:21 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=紫外线治疗皮肤病临床应用专家共识)])
紫外线治疗皮肤病临床应用专家共识
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186702, encodeId=cb741186e02a9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15236418022, createdName=ms1000001181118641, createdTime=Fri Jan 21 08:47:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181082, encodeId=dd841181082b7, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c15565180, createdName=黎莫愁, createdTime=Wed Jan 05 22:36:51 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083262, encodeId=353210832627e, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45125400457, createdName=ms9000001452514208, createdTime=Wed Dec 22 22:59:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952046, encodeId=05609520468f, content=刷点分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202148/1617894843737_1614372.png, createdBy=7d195472410, createdName=黎庶, createdTime=Mon Mar 29 14:17:04 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953789, encodeId=68bf953e8973, content=bucuobucuo,看一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bab5440056, createdName=ms8000001658197700, createdTime=Sun Apr 04 18:26:57 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2022-01-21 ms1000001181118641

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186702, encodeId=cb741186e02a9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15236418022, createdName=ms1000001181118641, createdTime=Fri Jan 21 08:47:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181082, encodeId=dd841181082b7, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c15565180, createdName=黎莫愁, createdTime=Wed Jan 05 22:36:51 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083262, encodeId=353210832627e, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45125400457, createdName=ms9000001452514208, createdTime=Wed Dec 22 22:59:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952046, encodeId=05609520468f, content=刷点分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202148/1617894843737_1614372.png, createdBy=7d195472410, createdName=黎庶, createdTime=Mon Mar 29 14:17:04 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953789, encodeId=68bf953e8973, content=bucuobucuo,看一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bab5440056, createdName=ms8000001658197700, createdTime=Sun Apr 04 18:26:57 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2022-01-05 黎莫愁

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186702, encodeId=cb741186e02a9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15236418022, createdName=ms1000001181118641, createdTime=Fri Jan 21 08:47:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181082, encodeId=dd841181082b7, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c15565180, createdName=黎莫愁, createdTime=Wed Jan 05 22:36:51 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083262, encodeId=353210832627e, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45125400457, createdName=ms9000001452514208, createdTime=Wed Dec 22 22:59:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952046, encodeId=05609520468f, content=刷点分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202148/1617894843737_1614372.png, createdBy=7d195472410, createdName=黎庶, createdTime=Mon Mar 29 14:17:04 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953789, encodeId=68bf953e8973, content=bucuobucuo,看一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bab5440056, createdName=ms8000001658197700, createdTime=Sun Apr 04 18:26:57 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2021-12-22 ms9000001452514208

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186702, encodeId=cb741186e02a9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15236418022, createdName=ms1000001181118641, createdTime=Fri Jan 21 08:47:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181082, encodeId=dd841181082b7, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c15565180, createdName=黎莫愁, createdTime=Wed Jan 05 22:36:51 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083262, encodeId=353210832627e, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45125400457, createdName=ms9000001452514208, createdTime=Wed Dec 22 22:59:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952046, encodeId=05609520468f, content=刷点分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202148/1617894843737_1614372.png, createdBy=7d195472410, createdName=黎庶, createdTime=Mon Mar 29 14:17:04 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953789, encodeId=68bf953e8973, content=bucuobucuo,看一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bab5440056, createdName=ms8000001658197700, createdTime=Sun Apr 04 18:26:57 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2021-03-29 黎庶

    刷点分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186702, encodeId=cb741186e02a9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15236418022, createdName=ms1000001181118641, createdTime=Fri Jan 21 08:47:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181082, encodeId=dd841181082b7, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c15565180, createdName=黎莫愁, createdTime=Wed Jan 05 22:36:51 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083262, encodeId=353210832627e, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45125400457, createdName=ms9000001452514208, createdTime=Wed Dec 22 22:59:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952046, encodeId=05609520468f, content=刷点分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202148/1617894843737_1614372.png, createdBy=7d195472410, createdName=黎庶, createdTime=Mon Mar 29 14:17:04 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953789, encodeId=68bf953e8973, content=bucuobucuo,看一下。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bab5440056, createdName=ms8000001658197700, createdTime=Sun Apr 04 18:26:57 CST 2021, time=2021-04-04, status=1, ipAttribution=)]
    2021-04-04 ms8000001658197700

    bucuobucuo,看一下。

    0